Faculty

	Eric D. Donnenfeld, MD (Chair) Clinical Professor of Ophthalmology New York University Langone Medical Center New York, New York Founding Partner Ophthalmic Consultants of Long Island and Connecticut Garden City, New York
	John A. Hovanesian, MD Specialist in Cataract, Refractive, Cornea, and Pterygium Surgery Harvard Eye Associates Laguna Hills, California
	Cathleen M. McCabe, MD Cataract, Refractive, and Anterior Segment Surgery Chief Medical Officer, Eye Health America Medical Director, The Eye Associates Bradenton, Florida
	Elizabeth Yeu, MD Virginia Eye Consultants Medical Director, CVP Mid-Atlantic Medical Director, Virginia Surgery Center Cornea, Cataract, External Disease, and Refractive Surgery Assistant Professor Department of Ophthalmology Eastern Virginia Medical School Norfolk, Virginia

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Eric D. Donnenfeld, MD, is a consultant for Allegro Ophthalmics, LLC, Allergan, Alcon, Avellino, Bausch & Lomb Incorporated, Beaver-Visitec International, BlephEx, CorneaGen, Covalent Laboratories, Dompé US, Inc, ELT Sight, EyePoint Pharmaceuticals, Foresight Labs, LLC, Glaukos Corporation, Ivantis Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Katena Products, Inc, LacriPen, LensGen, Mati Therapeutics, Inc, Merck & Co., Inc, Mimetogen Pharmaceuticals, Nanowafer, NovaBay Pharmaceuticals, Inc, Novaliq GmbH Germany, Novartis Pharmaceuticals Corporation, OcuHub LLC, Ocular Innovations, Oculis, Odyssey Medical, Inc, Omega Ophthalmics, Omeros Corporation, Oyster Point Pharma, Inc, Pfizer Inc, Physician Recommended Nutriceuticals, PogoTec, Rapid Pathogen Screening, Inc, Regener-Eyes, ReTEAR, Inc, Shire, Strathspey Crown, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, TearScience, Thea Pharmaceuticals Limited, TLC Laser Eye Centers, Veracity Innovations LLC, Versant Ventures, Visionary Ventures, Visus Therapeutics, and Zeiss; and has individual stocks or stock options in Avedro, Inc, CorneaGen, Covalent Laboratories, ELT Sight, EyePoint Pharmaceuticals, Glaukos Corporation, Ivantis Inc, LacriPen, LensGen, Mati Therapeutics, Inc, Mimetogen Pharmaceuticals, NovaBay Pharmaceuticals, Inc, OcuHub LLC, Ocular Innovations, Oculis, Orasis Pharmaceuticals, PogoTec, Rapid Pathogen Screening, Inc, Regener-Eyes, ReTEAR, Inc, Strathspey Crown, Surface, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Veracity, Versant Ventures, Visionary Ventures, and Visus Therapeutics.

John A. Hovanesian, MD, is a consultant for Abbott Medical Optics, AcuFocus, Inc, Aerie Pharmaceuticals, Inc, Alcon, Allegro Ophthalmics, LLC, Allergan, BlephEx, Eyedetec Medical, Glaukos Corporation, Guardion Health Sciences, Inc, IOP Ophthalmics, Ivantis Inc, Kala Pharmaceuticals, Katena Products, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Omeros Corporation, Sarentis Ophthalmics, Inc, Sensimed AG, Shire, TearLab Corporation, TearFilm Innovations Inc, Valeant, and Veracity Innovations LLC; is an advisory board member of Abbott Medical Optics, Aerie Pharmaceuticals, Inc, BlephEx, Cord LLC, Eyedetec Medical, Glaukos Corporation, Guardion Health Sciences, Inc, Ingenoeye LLC, IOP Ophthalmics, Ivantis Inc, Kala Pharmaceuticals, Katena Products, Inc, Ocular Therapeutix, Inc, Omeros Corporation, Shire, Sight Sciences, TearLab Corporation, Tear Film Innovations Inc, Valeant, and Veracity; is a contracted researcher for Abbott Medical Optics, AcuFocus, Inc, Aerie Pharmaceuticals, Inc, Alcon, Allergan, Cloudbreak Therapeutics, Cord LLC, Eyedetec Medical, Glaukos Corporation, Ingenoeye LLC, IOP Ophthalmics, Katena Products, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Omeros Corporation, Shire, TearFilm Innovations Inc, and Valeant; and has individual stocks or stock options in Alcon, Allegro Ophthalmics, Allergan, BlephEx, Eyedetec Medical, Glaukos Corporation, Guardion Health Sciences, Inc, Ingenoeye LLC, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, RxSIGHT, Sarentis Ophthalmics, Inc, Sight Sciences, and TearFilm Innovations Inc.

Cathleen M. McCabe, MD, is a consultant for Alcon, Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, EyePoint Pharmaceuticals, Eyevance, Imprimis Pharmaceuticals, Inc, iSTAR Medical, Ivantis Inc, LENSAR, LLC, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Omeros Corporation, Orasis Pharmaceuticals, Quidel Corporation, ScienceBased Health, Sight Sciences, Tarsus Pharmaceuticals, Inc, Visus Therapeutics, and Zeiss; is on the speakers bureau for Alcon, Allergan, Bausch & Lomb Incorporated, EyePoint Pharmaceuticals, Ivantis Inc, LENSAR, LLC, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Omeros Corporation, and Sight Sciences; and is a contracted researcher for Alcon, Glaukos Corporation, Ivantis Inc, Ocular Therapeutix, Inc, Ora, Inc, Orasis Pharmaceuticals, and Sun Pharmaceutical Industries, Inc.

Elizabeth Yeu, MD, is a consultant for Alcon, Allergan, Avedro, Bausch & Lomb Incorporated, Beaver-Visitec International, BlephEx, Bruder Healthcare, CorneaGen, Dompé US, Inc, Expert Opinion, EyePoint Pharmaceuticals, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, LENSAR, LLC, Merck & Co., Inc, Minosys Cellular Devices Inc, Novartis Pharmaceuticals Corporation, Ocular Science, Ocular Therapeutix, Inc, OCuSOFT Inc, Omeros Corporation, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Thea Pharmaceuticals Limited, Topcon Medical Systems, Inc, Visus Therapeutics, and Zeiss; is on the speakers bureau for Glaukos Corporation; is a contracted researcher for Alcon, Bio-Tissue, Ocular Science, TearLab Corporation, and Topcon Medical Systems, Inc; and has individual stocks or stock options in BlephEx, CorneaGen, Ocular Science, Oyster Point Pharma, Inc, and Tarsus Pharmaceuticals, Inc.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant financial relationships.

Planners and Managers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Medical Writer: Cheryl Guttman Krader has individual stocks or stock options in Johnson and Johnson Vision Care, Inc.